Becton, Dickinson and Company (NYSE:BDX) Holdings Lifted by Addenda Capital Inc.

Addenda Capital Inc. boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 38,484 shares of the medical instruments supplier’s stock after buying an additional 3,156 shares during the period. Addenda Capital Inc.’s holdings in Becton, Dickinson and Company were worth $8,731,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BDX. AE Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 36.2% during the second quarter. AE Wealth Management LLC now owns 2,482 shares of the medical instruments supplier’s stock valued at $580,000 after buying an additional 660 shares in the last quarter. Sei Investments Co. boosted its stake in Becton, Dickinson and Company by 7.3% during the second quarter. Sei Investments Co. now owns 222,580 shares of the medical instruments supplier’s stock valued at $52,016,000 after buying an additional 15,193 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Becton, Dickinson and Company by 12.1% during the second quarter. Thrivent Financial for Lutherans now owns 13,806 shares of the medical instruments supplier’s stock valued at $3,227,000 after purchasing an additional 1,490 shares during the last quarter. Summit Trail Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 5.3% during the second quarter. Summit Trail Advisors LLC now owns 1,422 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 71 shares during the last quarter. Finally, Holderness Investments Co. lifted its holdings in shares of Becton, Dickinson and Company by 27.3% during the second quarter. Holderness Investments Co. now owns 1,397 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.5 %

Shares of Becton, Dickinson and Company stock opened at $237.57 on Tuesday. The stock has a 50-day moving average price of $227.07 and a 200 day moving average price of $232.64. The company has a market cap of $68.90 billion, a P/E ratio of 40.00, a P/E/G ratio of 1.69 and a beta of 0.39. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the business earned $3.42 EPS. The business’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were paid a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.75%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Wall Street Analyst Weigh In

BDX has been the subject of several analyst reports. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $283.50.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 4,483 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the transaction, the executive vice president now directly owns 16,201 shares in the company, valued at approximately $3,807,235. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,747 shares of company stock valued at $1,949,520 in the last three months. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.